- 3 days ago
Rome Therapeutics’ CEO on the science of the 'Dark Genome' and last week’s $72M Series B extension
Rosana Kapeller explains how Rome is looking at areas of the genome that do not encode for traditional proteins as the basis of disease.
- 3 days ago
Generate Biomedicines' Mike Nally on Thursday's $273M Series C and computational drug development
Mike Nally describes Generate's near term programs how he sees computational advances changing where the field is headed over the long term.
- Sep 13
Moderna’s Head of R&D explains how mRNA is being tested with other emerging cancer modalities
Stephen Hoge explains how Moderna is partnering on programs that include CAR-T, TCRs, bi-specifics, and in-vivo editing programs.
- Sep 13
Moderna CEO Stéphane Bancel on Moderna’s business at its R&D Day in New York
Stéphane Bancel comments on the fall covid vaccine rollout, pushing into earlier stages of cancer, and rare diseases.
- Sep 11
Mariana Oncology’s CEO talks about radiopharmaceuticals and last week’s $175M Series B financing
Simon Read discusses the use cases for radiopharmaceuticals and why Mariana has chosen small cell lung cancer for its first indication.
- Sep 8
Brent Saunders talks about his priorities for growth at Bausch + Lomb
Brent Saunders describes a recent deal Bausch + Lomb has made in dry eye disease and his goal to push further into retinal diseases as well.
- Sep 6
Caribou Biosciences’ CEO on working toward a pivotal trial in 2nd line LBCL
Rachel Haurwitz describes recent data and the durability profile of Caribou’s allo CAR-T as the company plans to discuss a pivotal with FDA.
